5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 5.14▲ | 5.10▲ | 5.11▲ | 5.16▼ | 5.23▼ |
MA10 | 5.11▲ | 5.17▼ | 5.16▼ | 5.06▲ | 3.29▲ |
MA20 | 5.21▼ | 5.13▲ | 5.09▲ | 5.15▼ | 1.87▲ |
MA50 | 5.11▲ | 5.11▲ | 5.25▼ | 2.97▲ | 1.35▲ |
MA100 | 5.32▼ | 5.20▼ | 4.00▲ | 1.70▲ | 1.41▲ |
MA200 | 5.30▼ | 2.83▲ | 2.25▲ | 1.32▲ | 2.35▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.009▼ | -0.005▼ | 0.001▲ | -0.152▼ | 0.510▲ |
RSI | 49.641▼ | 50.902▲ | 51.753▲ | 62.707▲ | 75.951▲ |
STOCH | 49.934 | 14.547▼ | 23.097 | 48.138 | 82.241▲ |
WILL %R | -62.963 | -73.684 | -73.684 | -61.364 | -22.056▲ |
CCI | -11.864 | -13.202 | 9.501 | 47.951 | 77.642 |
Monday, August 18, 2025 04:40 AM
BELTSVILLE, Md., Aug. 07, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and ...
|
Friday, August 08, 2025 03:32 AM
GAAP net loss per share was $(11.29) for Q2 2025, missing the consensus GAAP EPS estimate of $(4.62) by a wide margin, mainly due to a $17.0 million up-front license fee. NextCure advanced both its ...
|
Friday, July 25, 2025 03:52 AM
(RTTNews) - Shares of NextCure Inc. (NXTC) are up nearly 30% at $6.60 in premarket trading on Friday, following encouraging preclinical data of its brittle bone disease drug candidate, NC605.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
19/08/25 | 5.24 | 5.30 | 4.95 | 5.09 | 34,500 |
18/08/25 | 5.03 | 5.63 | 5.01 | 5.26 | 93,100 |
15/08/25 | 5.216 | 5.216 | 5.011 | 5.115 | 8,000 |
14/08/25 | 5.089 | 5.17 | 5.018 | 5.148 | 5,500 |
13/08/25 | 4.81 | 5.23 | 4.81 | 5.19 | 27,900 |
12/08/25 | 4.91 | 4.93 | 4.76 | 4.835 | 18,356 |
11/08/25 | 4.91 | 4.98 | 4.75 | 4.80 | 17,300 |
08/08/25 | 4.91 | 5.28 | 4.85 | 4.87 | 14,800 |
07/08/25 | 4.90 | 5.42 | 4.90 | 5.095 | 25,300 |
06/08/25 | 5.002 | 5.16 | 4.91 | 5.16 | 15,945 |
|
|
||||
|
|
||||
|
|